This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pritchard, L. E. Articles by White, A. Search for Related Content PubMed PubMed Citation Articles by Pritchard, L. E. Articles by White, A.

Neuropeptide Processing and Its Impact on Melanocortin Pathways

Endocrine Sciences, Faculties of Life Sciences and Medical and Human Sciences, University of Manchester, Manchester M13 9NT, United Kingdom

Address all correspondence and requests for reprints to: Professor Anne White, Endocrine Sciences Research Group, CTF Building, 46 Grafton Street, Manchester M13 9NT, United Kingdom. E-mail: anne.white{at}manchester.ac.uk.

Proopiomelanocortin (POMC) is processed in an intracellular secretory pathway, primarily to enable release of ACTH from the pituitary and -MSH from hypothalamic neurons and skin. However, processing is incomplete and unprocessed POMC is secreted from all three tissues. This review considers intracellular processing of neuronal POMC as a key checkpoint that controls flux through hypothalamic melanocortin receptor pathways. Regulation of the convertase, proprotein convertase (PC)-1/3, which cleaves POMC is likely to determine the extent of POMC processing. Reduced PC1/3 activity, in both humans and rodents, leads to reduced melanocortin signaling and hence obesity. In contrast to POMC, posttranslational processing of proagouti-related peptide, an endogenous melanocortin-4 receptor antagonist, is efficient and is unlikely to represent a regulatory checkpoint. Because POMC is fully processed to ACTH and MSH peptides in secretory vesicles, unprocessed POMC, which is released from cells, must exit via an unregulated constitutive pathway. Therefore, the targeting of POMC to secretory granules controls the extent of POMC cleavage. There is evidence that PC1/3 is involved in cleavage of POMC in the trans-Golgi network and regulation of trafficking to the secretory pathway, in which it subsequently cleaves POMC to the melanocortin peptides. This would suggest that -MSH and ß-MSH may be subject to alternative sorting mechanisms, leading to heterogeneity in secretory granule content in POMC-producing cells. Overall, these studies implicate POMC processing as a key regulatory mechanism in the control of energy homeostasis.

This article has been cited by other articles:

				J. W. M. Creemers, Y. S. Lee, R. L. Oliver, M. Bahceci, A. Tuzcu, D. Gokalp, J. Keogh, S. Herber, A. White, S. O'Rahilly, et al. Mutations in the Amino-Terminal Region of Proopiomelanocortin (POMC) in Patients with Early-Onset Obesity Impair POMC Sorting to the Regulated Secretory Pathway J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4494 - 4499. [Abstract] [Full Text] [PDF]